About Takeda Oncology


Sophie Opdyke

Head, Global Commercial Oncology, Oncology Business Unit

Sophie Opdyke is Head of Global Commercial Oncology (GCO), OBU at Takeda. She joined the company in April 2020 and is responsible for driving the global growth strategy for the oncology business unit and for ensuring optimal commercialization for the oncology products in early and late development phases.

Prior to joining Takeda, Ms. Opdyke was Vice President and General Manager of Ferring Oncology, where she was responsible for building the new US oncology division, leading its day-to-day operations and shaping its long-term strategy to launch a novel gene therapy for bladder cancer.

Prior to Ferring, Ms. Opdyke spent 20 years at Pfizer, where she had numerous roles of increasing responsibility across commercial, business development and strategy. Notably, Ms. Opdyke was responsible for developing and directing the company’s strategies in Immuno-Oncology and leading all commercial activities, from pre-clinical through launch, in close collaboration with R&D and regional organizations and championing business development opportunities in the field. During her tenure, Sophie was instrumental in building and leading Pfizer’s Global Biosimilars organization, driving a core component of Pfizer’s biotherapeutics strategy.

Ms. Opdyke holds an MBA from Columbia Business School and a PharmD and Master of Pharmaceutical Business Management from Paris Descartes University.